ライフサイエンスコーパス: menopausal status

1 n terms of both BCSS and OS, irrespective of menopausal status.

2 rolled for age, total body fat, smoking, and menopausal status.

3 tality from breast cancer, regardless of the menopausal status.

4 ting CSF1 levels and breast cancer varies by menopausal status.

5 cer and reproductive characteristics vary by menopausal status.

6 d 2001, participants provided information on menopausal status.

7 (HRT), and estrogen exposure on the basis of menopausal status.

8 FFM, or physical activity levels in women by menopausal status.

9 sidered age, smoking, physical activity, and menopausal status.

10 ependent risk contribution from both age and menopausal status.

11 rhea, pre-operative alcohol consumption, and menopausal status.

12 ographic breast density, tumor histology, or menopausal status.

13 an association in women was not explained by menopausal status.

14 redicts poor clinical outcomes regardless of menopausal status.

15 In addition, we examined associations by menopausal status.

16 dependent of breast density, tumor type, and menopausal status.

17 disease, tumor grade, age at diagnosis, and menopausal status.

18 ic acid; family history of breast cancer; or menopausal status.

19 or status, progesterone receptor status, and menopausal status.

20 hnicity, body mass index, energy intake, and menopausal status.

21 omen and lower than in whites, regardless of menopausal status.

22 ion or diagnosed high cholesterol level, and menopausal status.

23 ) (OR = 0.50, 95% CI: 0.25, 1.01) instead of menopausal status.

24 isms of sudden coronary death, which vary by menopausal status.

25 human breast carcinogenesis, dependent upon menopausal status.

26 re were significant, they were unaffected by menopausal status.

27 enhancement correlated with patient age and menopausal status.

28 s well as differences by body mass index and menopausal status.

29 obesity, and metabolic syndrome depending on menopausal status.

30 .0998 for DFS; 0.027 for OS), independent of menopausal status.

31 Post hoc analyses were performed by menopausal status.

32 impact on DRFI as a function of subtype and menopausal status.

33 her than tumor burden, molecular subtype, or menopausal status.

34 x regression models stratified for nodal and menopausal status.

35 nction, with an emphasis on the influence of menopausal status.

36 trend persisted regardless of age, race, and menopausal status.

37 index, family history of breast cancer, and menopausal status.

38 sk, overall and by breast cancer subtype and menopausal status.

39 ination KARISMA phase II trial stratified by menopausal status.

40 serologic evaluations were used to determine menopausal status.

41 , 95% confidence interval: 0.61, 1.33) or by menopausal status.

42 ll reduction in risk of BC, independently of menopausal status.

43 CVD, but most studies retrospectively assess menopausal status.

44 able to assess effects on body iron, sex, or menopausal status.

45 idermal growth factor receptor 2 (HER2), and menopausal status.

46 in analyses stratified by family history or menopausal status.

47 , tumor characteristics, breast density, and menopausal status.

48 lyses, mostly in subgroups defined by age or menopausal status.

49 global burden and trends in breast cancer by menopausal status.

50 29% were postmenopausal, and 2% were unknown menopausal status; 49.5% were HmR positive; 33.5% were H

51 HER2+/ER- subtype did not vary with race or menopausal status (6%-9%).

52 Furthermore, apart from age and menopausal status a statistically significant positive c

53 With menopausal status added to the model, naturally and surg

54 Stratification was by menopausal status, adjuvant endocrine therapy plan, and

55 This is the first study to assess how menopausal status affects vascular responses to chemothe

56 index (BMI); the endometrial model included menopausal status, age at menopause, BMI, smoking, oral

57 use, other MHT use, age at first live birth, menopausal status, age at menopause, family history of b

58 , parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone repl

59 We found that menopausal status, age, and HIV were independently assoc

60 nsideration of sex differences, sex hormones/menopausal status, age, and other reproductive informati

61 en 1996 and 2001 to determine the effects of menopausal status, age, race, and use of hormone replace

62 Test performance was similar across menopausal status, age, stage, grade, ethnicity, and his

63 sted within strata defined by levels of BMI, menopausal status, alcohol consumption, and C-reactive p

64 This association did not vary by menopausal status, although IBC patients were more likel

65 ciation between persistent mood symptoms and menopausal status and 2) factors that increase a woman's

66 Findings suggest that menopausal status and age at menopause may play a role i

67 on by risk group and exploratory analyses by menopausal status and age.

68 Analyses stratified by menopausal status and body mass index also showed no cle

69 no history of depression is associated with menopausal status and changes in reproductive hormones i

70 s annual screen by 10-year age groups and by menopausal status and current postmenopausal HT use.

71 Overall, associations were homogeneous by menopausal status and ER and PR expression in tumors.

72 regression models and stratified analyses by menopausal status and ER/PR status.

73 Subgroup analyses were performed by menopausal status and estrogen receptor (ER) and progest

74 risk and whether the associations varied by menopausal status and estrogen receptor (ER) and progest

75 sical activity in older men and women and in menopausal status and estrogen use in women.

76 rces, season of measurement, and, for women, menopausal status and estrogen use.

77 ber intake and risk of breast cancer (BC) by menopausal status and hormone receptor expression in tum

78 Although menopausal status and hormone replacement therapy use do

79 nges were examined in relation to changes in menopausal status and in levels of estradiol and follicl

80 collection, fasting status, and (for NHS II) menopausal status and luteal day of menstrual cycle for

81 isk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT

82 interval (biennial vs annual) stratified by menopausal status and race and ethnicity (Asian or Pacif

83 dict skin hydration, subject's age, pre/post-menopausal status and smoking status from the leg skin m

84 A significant interaction between menopausal status and treatment group was observed for D

85 Tests of an interaction between menopausal status and treatment were nonsignificant.

86 esults were observed in subgroups defined by menopausal status and type of adjuvant systemic treatmen

87 ssociation was not significantly modified by menopausal status and was independent of age at menarche

88 oronary artery disease (CAD) is modulated by menopausal status and/or age.

89 ysical activity, dyslipidemia, hypertension, menopausal status, and adiposity.

90 yses stratified by estrogen receptor status, menopausal status, and age, a higher waist-to-hip ratio

91 ments and adjusted for age, education, race, menopausal status, and baseline reading ability, anxiety

92 ontinue to investigate links between parity, menopausal status, and biological age using targeted phy

93 e exposure, family history of breast cancer, menopausal status, and body mass index x recent hormone

94 We stratified by smoking, menopausal status, and breast cancer-related variables.

95 iate adjustment for baseline age, ethnicity, menopausal status, and changes in comorbidities and life

96 nd Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body m

97 rian cancer and 116 controls matched on age, menopausal status, and date of blood donation were inclu

98 and left ventricular ejection fraction <55%, menopausal status, and FSH were not associated with BNP

99 s were age, body mass index, blood donation, menopausal status, and HFE genotype.

100 dex, alcohol intake, marital status, parity, menopausal status, and history of myocardial infarction.

101 n, use of lipid-lowering medication, season, menopausal status, and hormone replacement therapy.

102 001) independent of risk factors, age, race, menopausal status, and hormone therapy.

103 ge, race, smoking, blood pressure, diabetes, menopausal status, and hormone use, the odds ratios (95%

104 re in middle-aged men and women by sex, age, menopausal status, and level of obesity, and to compare

105 used as risk stratification tools; and age, menopausal status, and medical comorbidities should be c

106 gitudinally examined the relations of aging, menopausal status, and physical activity to weight and w

107 ucation, age at menarche, pregnancy history, menopausal status, and postmenopausal hormone use, durat

108 by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis a

109 rmal women matched for age, body-mass index, menopausal status, and race, using dual-energy x-ray abs

110 ptor (ER)/progesterone receptor (PR) status, menopausal status, and racial and ethnic subgroups.

111 of 4), stratified by previous chemotherapy, menopausal status, and region, to receive standard-of-ca

112 nd adjusted for body mass index, parity, and menopausal status, and the area under the receiver opera

113 ontrolled for the age of the patients, their menopausal status, and the orientation of the MR images

114 ity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) stat

115 gs from those trials and relate them to age, menopausal status, and tumour oestrogen-receptor concent

116 rvival estimated according to patients' age, menopausal status, and tumour oestrogen-receptor concent

117 sy exists regarding the extent to which age, menopausal status, and/or lifestyle behaviors account fo

118 biome signatures associated with smoking and menopausal status are consistent with previous findings

119 intake, smoking status, alcohol intake, and menopausal status as potential covariates.

120 a, body mass index [BMI], diabetes mellitus, menopausal status) as well as indicators of systemic inf

121 ; two controls were matched per case on age, menopausal status at blood draw and diagnosis, fasting s

122 se observations did not vary by adult BMI or menopausal status at blood draw.

123 ampsia and breast cancer risk is modified by menopausal status at breast cancer diagnosis.

124 , number of lymph nodes, estrogen receptors, menopausal status at diagnosis, and disease-free interva

125 prognosis and age at menarche and menopause, menopausal status at diagnosis, smoking history, or prio

126 these measures of adiposity vary by age and menopausal status at the time of diagnosis.

127 88 and 1994, was to assess associations with menopausal status based either on menstrual cycle patter

128 smoking, use of hormone replacement therapy, menopausal status, baseline menopausal symptoms, and tre

129 lyses adjusted for stage, comorbidities, and menopausal status, Black patients had lower odds of elev

130 However, age, menopausal status, BMI, and use of hypertensive medicati

131 in pre- and perimenopausal women (i.e., age, menopausal status, body composition, and lifestyle behav

132 ciation did not differ appreciably by stage, menopausal status, body mass index, or estrogen receptor

133 anthropometric and biochemical variables, or menopausal status (breast cancer), higher serum iron con

134 ger sample size with detailed information on menopausal status, breast cancer subtypes, and repeated

135 eptor status and age at diagnosis (proxy for menopausal status) by using conditional logistic regress

136 inants of calcium absorption efficiency were menopausal status, calcium intake, and serum estradiol a

137 cent density were evident overall and within menopausal status categories.

138 n, the vascular risk factors increase as the menopausal status changes.

139 ER status, tumor stage, histological grade, menopausal status, chemotherapy or statin use in either

140 survival) or other patient characteristics (menopausal status, chemotherapy or statin use), we analy

141 After adjustment for age, race, menopausal status, clinical stage, tumor size, and famil

142 rom the entries of patient information (age, menopausal status, comorbidity estimate) and tumor stagi

143 ardiovascular risk status, diuretic use, and menopausal status, confirmed a significant association o

144 Anthropometric measures and menopausal status contribute to a large variability in c

145 definition of the following important terms: menopausal status, CRA (early and late), temporary CRA,

146 The effects of menopausal status, cyst size and other features, and the

147 Menopausal status, cyst size, and other cyst features si

148 spective review was performed for women with menopausal status data who were treated for breast cance

149 urine specimens was one-to-one matched (age, menopausal status, date of urine collection, and day of

150 and this association was age, pregnancy, and menopausal status dependent.

151 Endocrine therapy and menopausal status did not affect results.

152 ER, stage or menopausal status did not modify the effect of post-diag

153 family history remained significant, whereas menopausal status did not.

154 ing factors, including current body size and menopausal status, did not alter the findings.

155 to the patients' axillary lymph node status, menopausal status, disease status, disease-free survival

156 sessed effects of baseline iron status, sex, menopausal status, duration of intervention, iron form,

157 Eligible patients-ie, any menopausal status, Eastern Cooperative Oncology Group pe

158 adjustment for age, alcohol intake, gender, menopausal status, education, body mass index, and pover

159 After adjustment for age, gender, menopausal status, ethnicity, center, smoking, and alcoh

160 The lifestyle extended model included menopausal status, family history of breast cancer, body

161 t interaction between study intervention and menopausal status for EFS and OS, with a benefit of addi

162 risk and chemotherapy benefit predictions by menopausal status for patients with HR+/human epidermal

163 interaction between history of migraine and menopausal status for the prediction of VMS was also ide

164 database contains information on HRT use and menopausal status for women with a recent MI.

165 trial were similar with respect to age, sex, menopausal status, glucocorticoid dosage and duration, d

166 h some analyses, including associations with menopausal status, hormone receptor expression, and hist

167 t and adjusted for number of positive nodes, menopausal status, hormone receptor status, and tumor si

168 = .033), in which analysis was adjusted for menopausal status, hormone receptor status, treatment, n

169 ss index, physical activity, alcohol intake, menopausal status, hormone replacement therapy, aspirin

170 , stage, grade, treatments, body mass index, menopausal status, hormone therapy use, family history o

171 ndomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intentio

172 of asthma and respiratory symptoms differ by menopausal status in a longitudinal population-based stu

173 The impact of sex and menopausal status in Alzheimer's disease remains underst

174 cross-sectional differences in MD by age and menopausal status in over 11,000 breast-cancer-free wome

175 whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth c

176 To examine the effect of menopausal status in the absence of data on individual p

177 The relative contribution of age versus menopausal status in the development of CAD in women rem

178 We attempted to (1) define menopausal status in the setting of adjuvant chemotherap

179 oxidative stress are implicated, the role of menopausal status in vascular mechanisms of increased CV

180 older adulthood (ages >/=70 years); or 2) by menopausal status in women and stratification by age 50

181 , HDL and LDL cholesterol, R-R interval, and menopausal status in women showed QTc and JTc were nonpr

182 tratified by gender and further according to menopausal status in women.

183 gy intake, physical activity, education, and menopausal status (in women).

184 available chemoprevention regimens differ by menopausal status, including tamoxifen 20 mg once daily

185 Within-woman change in menopausal status, increased levels of follicle-stimulat

186 Age, rather than menopausal status, independently contributed to damage a

187 The authors assessed age, menopausal status, index breast cancer histologic result

188 hypertensive, with information on ethnicity, menopausal status, insulin-resistant status, and 21 loci

189 sus menopausal status, we fit a hypertension-menopausal status interaction term and adjusted for age.

190 Age rather than menopausal status is a strong independent predictor of d

191 Assessment of menopausal status is critical; ovarian suppression or ab

192 nd pharmacologic hormonal effects, including menopausal status, lactation, hormone replacement therap

193 Conclusion Hormonal effects, including menopausal status, lactation, HRT, and tamoxifen therapy

194 stolic, and pulse pressure, body mass index, menopausal status, levels of total and low-density lipop

195 l groups (patients matched for age, sex, and menopausal status), made comparisons with established da

196 se subjects (n = 1108) and age-, gender- and menopausal status-matched participants in the Framingham

197 Neither sex nor menopausal status may be relevant in antidepressant trea

198 ining these influences in the context of the menopausal status might help identify subgroups of patie

199 Subject characteristics (eg, menopausal status) modulated the dietary requirement for

200 When stratified by menopausal status, no noteworthy associations were obser

201 sociated with grade, but not associated with menopausal status, nodal status, or tumor size.

202 nonresponders were not distinguished by age, menopausal status, nor several cephalometric or anthropo

203 s by age, age at menarche, age at menopause, menopausal status, number of pregnancies, breast feeding

204 Analyzing data without regard to sex or menopausal status obscured group differences in circuit-

205 interactions between MAF-positive status and menopausal status on efficacy of zoledronic acid.

206 Effects of menopausal status on grip and pinch strength did not var

207 act with hormonal birth control use and with menopausal status on risk of YOBC.

208 However, the effect of risk factors and menopausal status on the mechanism of sudden coronary de

209 Abeta-PET was not associated with menopausal status or age.

210 association might not vary substantially by menopausal status or estrogen receptor status.

211 Mutated gene, menopausal status or having preemptive oophorectomy did

212 iation, either overall or when stratified by menopausal status or hormone receptor status.

213 res in 19 countries, enrolled women with any menopausal status or men, aged >=18 years (>=20 years in

214 not observe any significant interactions by menopausal status or other participant characteristics.

215 etween the two cohorts might be explained by menopausal status or simply by chance.

216 No meaningful difference was seen by menopausal status or type of beverage consumed.

217 FN after adjustment for age, weight, height, menopausal status or use of hormone replacement therapy,

218 t differ according to age, CVD risk factors, menopausal status, or anticancer treatment.

219 t modified or confounded by body mass index, menopausal status, or caloric intake during the past yea

220 ot vary by alcohol intake, multivitamin use, menopausal status, or oral contraceptive use.

221 erences in smoking history, body mass index, menopausal status, or personal or family history of cent

222 tected was not influenced by breast density, menopausal status, or the histologic features of the pri

223 not vary by body mass index, smoking status, menopausal status, or time between urine collection and

224 B-14 through 15 years, irrespective of age, menopausal status, or tumour oestrogen-receptor concentr

225 m the bed or used throughout the night; with menopausal status; or with the cases' hormone receptor s

226 oking, parity and duration of breastfeeding, menopausal status, oral contraceptive use, body mass ind

227 Exogenous estrogen use (P < .001) and menopausal status (P = .007) correlated significantly wi

228 for node status, tumor size, treatment, and menopausal status (P = 0.005 and P < 0.001, respectively

229 o exhibited the significant association with menopausal status (p = 0.008), lymph node status (p = 0.

230 .6; P for trend = .002), and did not vary by menopausal status (P for interaction = .95).

231 The association varied by menopausal status (P(heterogeneity) = 0.009).

232 Because choline needs vary by age, sex, and menopausal status, participants were segregated into cor

233 and c-erbB-2 status) and patient parameters (menopausal status, personal history of breast carcinoma)

234 ng, oral contraceptive use, body mass index, menopausal status, postmenopausal hormone therapy use, d

235 case were randomly chosen, matched for age, menopausal status, postmenopausal hormone use, and day,

236 ny), adjuvant chemotherapy (none v any), and menopausal status (pre-, peri-, or postmenopausal).

237 tus [one to three v > three positive nodes], menopausal status [pre- v postmenopausal women], estroge

238 oost or no boost, with minimisation for age, menopausal status, presence of extensive ductal carcinom

239 PE demonstrated significant association with menopausal status, prior breast radiation therapy, hormo

240 Knowledge of menopausal status, prior chemotherapy, and ESR genotype

241 Age, menopausal status, prior UTI, and host genetics were top

242 erval (annual, biennial, or triennial), age, menopausal status, race and ethnicity, family history of

243 ty, education, smoking, parity, anxiety, and menopausal status (relative to stable body fat, gain: od

244 Further stratification by menopausal status resulted in the same conclusion.

245 the absence of data on individual patients' menopausal status, results for female patients younger o

246 Both gender and menopausal status should be considered when choosing an

247 Menopausal status should be considered when switching to

248 Comparison of treatment response rates by menopausal status showed that premenopausal women respon

249 results were found after adjusting for age, menopausal status, smoking habit, and sexual exposure hi

250 ls; investigated effect modification by sex, menopausal status, smoking, and age; and calculated popu

251 These results were independent of age, menopausal status, smoking, diabetes, hypertension, and

252 OR(Q4) = 0.5, (0.3, 0.8), adjusted for age, menopausal status, soy protein, fibroadenoma history, fa

253 status, type and timing of systemic therapy, menopausal status, statin use, and treating centre.

254 status, type and timing of systemic therapy, menopausal status, statin use, and treatment centre) to

255 The results of an analysis stratified by menopausal status suggested a similar pattern.

256 years for sociodemographic characteristics, menopausal status, surgeries, body mass index, medicatio

257 assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy c

258 or status, ERBB2 status, histologic subtype, menopausal status, treatment duration, and survival stat

259 IDFS) and locoregional therapy, adjusted for menopausal status, treatment group, recurrence score, tu

260 Risk estimates did not vary by menopausal status, tumor invasiveness, or estrogen recep

261 Random assignment was stratified by menopausal status, tumor size, and center.

262 ct of LA was similar in subgroups defined by menopausal status, tumor size, nodal metastases, and hor

263 In a model that included age, race, obesity, menopausal status, tumor size, nodal status, treatment a

264 body mass index, lifetime physical activity, menopausal status, use of estrogen, and smoking.

265 iates (age, season of vitamin D measurement, menopausal status, use of hormone replacement therapy, a

266 ive factors (ages at menarche and menopause, menopausal status, use of oral contraceptives, and menop

267 ients and stratified by clinical subtype and menopausal status using inverse probability treatment we

268 formation on menstrual patterns to determine menopausal status using latent class analysis.

269 Logistic regression subgroup according to menopausal status was also performed.

270 Menopausal status was associated with accelerated lung f

271 Menopausal status was defined as nonmenopausal, transiti

272 Menstrual cycle-based menopausal status was defined for women who had not had

273 Menopausal status was defined using age as a proxy, wher

274 Menopausal status was determined from menstrual history,

275 , a significant interaction of WSHT group by menopausal status was found for systolic blood pressure

276 Menopausal status was not associated with a dysbiotic sh

277 Change in menopausal status was not associated with weight gain or

278 When matched the participants by age, post-menopausal status was still associated with a higher ris

279 sess the relative contribution of age versus menopausal status, we fit a hypertension-menopausal stat

280 Increasing age and post-menopausal status were associated with the presence of t

281 l activity, visceral adipose tissue, HIV and menopausal status were included as confounders.

282 Physical activity levels and menopausal status were included as covariates.

283 This association is independent of menopausal status, which remains an independent predicto

284 d 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-

285 ntrols, apart from a modest association with menopausal status with an increased risk of 1.53 and 1.4

286 multinational trial in adults of any sex or menopausal status with hormone receptor-positive, HER2-n

287 ty, age at first birth, age at menarche, and menopausal status with percent density and dense area as

288 ast cancer are associated with the patient's menopausal status, with a typical kinetic pattern of mal

289 tion between the kinetic characteristics and menopausal status, with an odds ratio of 2.94 for the la

290 garette smoking, diabetes, vascular disease, menopausal status (women only), and age.

291 ge, smoking, postmenopausal hormone use, and menopausal status, women with increased BMI (> or =27 kg

292 xamined cross-sectionally the association of menopausal status, years since last menstruation, and ho